Answers are grounded in this paper and cite their sources.
Specific tumor biomarkers visualization by molecular magnetic resonance imaging (MRI) enables early cancer detection before morphologic changes appear. Herein, we designed a peptide targeting moiety (GEVMPTLDMALFDWTDYEDLKP) for the extracellular emerging biomarker Netrin‐1, which was first conjugated to a DOTA‐like chelator ( G ). 111 In‐ G highlighted small tumors in an orthotopic murine model of triple‐negative metastatic breast cancer (4T1) by single‐photon emission computerized tomography (SPECT). Nevertheless, 111 In‐ G had very high kidney uptake which prevailed 24 h post‐injection. To prevent potential toxicity for MRI Gd‐analog, injected in higher dose due to MRI’s low sensibility, we developed a novel targeted liposome formulation, ( 111 In)‐Gd‐L G . Liposomes contain PEGylated phospholipids functionalized with the new targeting peptide and amphiphilic Gd 3+ / 111 In 3+ chelates enabling multimodal MRI and/or SPECT detection. The formulation was optimized and characterized by dynamic light scattering and 1 H relaxometry. In the same 4T1 murine model, ex vivo biodistribution evidenced significantly reduced liposomes kidney uptake (4 vs. 137%ID/g for 111 In‐Gd‐L G versus 111 In‐ G , 4 h post injection), retaining tumor detection capabilities. Successful in vivo MRI visualization of small tumors (<50 mm 3 ) at 0.03 mmol/kg Gd dose, provided similar signal enhancement as the clinical agent Dotarem at a 7‐fold higher dose. Data reinforce Netrin‐1’s potential targeting as cancer‐specific imaging approaches.
No takes yet. Share an insight, caveat, or question.
Patou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: